INS and metabolic syndrome: Among 25 participants with insulin resistance and metabolic syndrome, fenofibrate reduced plasma TG as well as inflammatory markers interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP), but did not improve insulin sensitivity [92].